Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28054561 | 1.00 | KMT2A (0.41) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL29036117 | 0.92 | KMT2A (0.45) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL2358897 | 0.88 | MDM2 (0.43) | KMT2AFABP5FABP7MDM2PPARG | |
| SCHEMBL2311742 | 0.88 | MDM2 (0.43) | KMT2AFABP5FABP7MDM2PPARG | |
| SCHEMBL18989109 | 0.85 | ANPEP (0.40) | KMT2AFABP5FABP7TP53PPARG | |
| SCHEMBL28094649 | 0.84 | SLC1A3 (0.42) | KMT2AFABP5FABP7PPARGPPARA | |
| SCHEMBL1514601 | 0.84 | FABP5 (0.43) | KMT2AFABP5FABP7PPARGPPARA | |
| SCHEMBL7128599 | 0.82 | KMT2A (0.47) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL28888234 | 0.81 | KMT2A (0.46) | KMT2AFABP5FABP7MDM4TP53 | |
| SCHEMBL3590767 | 0.80 | KMT2A (0.43) | KMT2AFABP5FABP7MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022200-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-9464057-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20160194286-A1 | NEW ANTI-MALARIAL AGENTS | UNIVERSITY OF WASHINGTON | 2016-07-07 | — | — | US | disclosed |
| EP-3022200-A1 | NEW ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008246-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194286-A1 | NEW ANTI-MALARIAL AGENTS | CYP51A1, QDPR, G6PD | KMT2A 1992/4885FABP5 3530/4885FABP7 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.